🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,180 results for “Takeda Pharmaceuticals International AG” Clear

  1. Leuprorelin

    Takeda Pharmaceuticals International AG

    Prostate Cancer

    phase 3 small molecule completed

    1 trial

  2. Leuprorelin SR

    Takeda Pharmaceuticals International AG

    Prostatic Neoplasms, Locally Advanced

    phase 3 small molecule completed

    1 trial

  3. Lifestyle modification

    Takeda Pharmaceuticals International AG

    Type 2 Diabetes

    phase 3 other completed

    1 trial

  4. Lifitegrast

    Takeda Pharmaceuticals International AG

    Dry Eye Disease

    phase 3 small molecule completed

    3 trials

  5. Lifitegrast

    Takeda Pharmaceuticals International AG

    Keratoconjunctivitis Sicca

    phase 3 small molecule completed

    1 trial

  6. Lisdexamfetamine Dimesylate (LDX)

    Takeda Pharmaceuticals International AG

    ADHD

    phase 3 small molecule completed

    3 trials

  7. Lisdexamfetamine dimesylate

    Takeda Pharmaceuticals International AG

    Binge Eating Disorder

    phase 3 small molecule completed

    2 trials

  8. Low-dose rtPA

    Takeda Pharmaceuticals International AG

    Ischemic Stroke

    phase 3 small molecule completed

    1 trial

  9. Lu AA21004

    Takeda Pharmaceuticals International AG

    Major Depressive Disorder

    phase 3 small molecule completed

    1 trial

  10. Lubiprostone

    Takeda Pharmaceuticals International AG

    Irritable Bowel Syndrome With Constipation

    phase 3 small molecule completed

    1 trial

  11. Lubiprostone

    Takeda Pharmaceuticals International AG

    Constipation - Functional

    phase 3 small molecule completed

    1 trial

  12. MMX Mesalamine/Mesalazine (Low Dose)

    Takeda Pharmaceuticals International AG

    Ulcerative Colitis

    phase 3 small molecule completed

    1 trial

  13. MOVIPREP

    Takeda Pharmaceuticals International AG

    Bowel Preparation Prior to Endoscopic, Radiological and Other Examinations as Well as to Surgical Procedures Which Require Empty Bowel.

    phase 3 small molecule completed

    1 trial

  14. Magnesium Pantoprazole

    Takeda Pharmaceuticals International AG

    GERD

    phase 3 small molecule completed

    1 trial

  15. Magnesium Pantoprazole 20 mg

    Takeda Pharmaceuticals International AG

    Gastric pH Control

    phase 3 small molecule terminated

    1 trial

  16. Maribavir

    Takeda Pharmaceuticals International AG

    Cytomegalovirus (CMV)

    phase 3 small molecule active

    6 trials

  17. Matching Placebo for TAK-279 Dose A, ZASOCITINIB, Matching Placebo for TAK-279 Dose B, ZASOCITINIB

    Takeda Pharmaceuticals International AG

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  18. Matching Placebo for TAK-279 Dose B, ZASOCITINIB, ZASOCITINIB, Matching Placebo for TAK-279 Dose A

    Takeda Pharmaceuticals International AG

    Active Psoriatic Arthritis Stratified by Prior Biologic Use

    phase 3 small molecule active

    1 trial

  19. Matching Placebo for TAK-279, ZASOCITINIB

    Takeda Pharmaceuticals International AG

    Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  20. Metformin on top of intensive insulin therapy

    Takeda Pharmaceuticals International AG

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  21. Mezagitamab

    Takeda Pharmaceuticals International AG

    Immune Thrombocytopenic Purpura (ITP)

    phase 3 small molecule active

    2 trials

  22. Mezagitamab

    Takeda Pharmaceuticals International AG

    Chronic Primary Immune Thrombocytopenia

    phase 3 small molecule active

    1 trial

  23. Mezagitamab

    Takeda Pharmaceuticals International AG

    Kidney Disease

    phase 3 small molecule active

    2 trials

  24. Mezagitamab, Mezagitamab placebo-matching injection administered SC

    Takeda Pharmaceuticals International AG

    IgAN is Primary Immunoglobulin A Nephropathy (IgAN) (also known as Berger's disease)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources